Standout Papers
Citation Impact
Citing Papers
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
2017
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 StandoutScience
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
2016
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2021
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
2013
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
2014
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
2017
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
2010
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
2010
A view on drug resistance in cancer
2019 StandoutNature
Therapeutic cancer vaccines: are we there yet?
2010
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
2015
ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
2011
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
Paclitaxel (Taxol)
1995 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Vemurafenib in melanoma
2013
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Improved Endpoints for Cancer Immunotherapy Trials
2010
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
2011
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma
2012
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
2016
Cancer immunotherapy comes of age
2011 StandoutNature
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
2013
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
2012
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Retinoids: present role and future potential
1999
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network
2014
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
2011
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Hepatocellular carcinoma
2022 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances
2009
Radioiodine Treatment of Metastatic Thyroid Cancer: Relative Efficacy and Side Effect Profile of Preparation by Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin
2012
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
2000
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
2015
Tremelimumab: A Review of Development to Date in Solid Tumors
2013
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
2016
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
2006
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
2013 StandoutScience
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer
2011
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
2013
Works of E. Eisenhauer being referenced
Successful re-treatment with taxol after major hypersensitivity reactions.
1993
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
1994
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial
2006
Phase II Trial of 13-cis-Retinoic Acid Plus Interferon in Non-Small-Cell Lung Cancer: For the National Cancer Instit ute of Canada Clinical Trials Group
1994
RECIST revisited: A review of validation studies on tumour assessment
2006
Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer
1992
Phase II study of acivicin in non-small cell lung cancer: A national cancer institute of Canada study
1987
Carboplatin versus cisplatin
1993